Zydus has developed an innovative formulation of Semaglutide Injection in a prefilled cartridge administered using a reusable patient-friendly pen device
The product is bioequivalent and therapeutically equivalent to Fresenius Kabi’s reference drug (NDA 212832)
The product addresses a market with approximately $66.8 million in annual sales as of December 2025.
Sodium Phosphates Injection is indicated as a source of phosphorus, for addition to large volume intravenous fluids, to prevent or correct hypophosphatemia in patients with restricted or no oral intake
If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations
Company to launch product after the expiry of semaglutide patent in India
Intas becomes the first and only company in India to offer IVF and gynecology therapies with needle-free injections
According to IQVIA sales data for the 12-month period ending October 2025, the Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) market2 achieved annual sales of approximately $67.6 million
Glenmark's Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial is bioequivalent and therapeutically equivalent to the reference listed drug
Subscribe To Our Newsletter & Stay Updated
